Benzocaine Dose-Response Seen Strongest In Severe Toothache Pain – CHPA
This article was originally published in The Tan Sheet
Executive Summary
The dose-response relationship of 10% and 20% strengths of benzocaine is particularly significant for patients with severe toothache pain, data forwarded to FDA by the Consumer Healthcare Products Association suggests
You may also be interested in...
OTC Firms Try Again For Benzocaine Monograph Status
Labels for benzocaine-containing oral analgesics would include pictograms in the Drug Facts box to show consumers how much product to use, under a proposal by the Consumer Healthcare Products Association
Benzocaine studies
A retrospective analysis of the dose-response relationship between 10% and 20% strengths of benzocaine "does not adequately support the dose response" of drug, FDA says in Oct. 29 letter responding to CHPA data submission (1"The Tan Sheet" July 8, 2002, p. 15). Agency reiterates call for one efficacy study to evaluate both 10%, 20% benzocaine compared with placebo for toothache. In addition, FDA advises study labeling must include language that directs consumer to seek treatment if relief is not obtained after several doses. Finally, agency requests updated assessment of methemoglobinemia cases associated with benzocaine use...
Benzocaine Repeat-Dosing, Three-Arm Trials Recommended By FDA’s Ganley
A three-arm benzocaine study is necessary to determine whether the existing 20% and 10% strengths are equally effective for toothache pain relief, according to FDA Division of OTC Drug Products Director Charles Ganley, MD